Sweden and the Netherlands, represented by Scandinavian CRO (SCRO) and Cardialysis, are uniting in a long-term collaboration to accelerate innovation within the life sciences. On October 12th, the two companies signed a Memorandum of Understanding in the presence of the King and Queen of each respective country during their visit to the SciLifeLab in Solna, Sweden.
Scandinavian CRO (SCRO) is a full-service Contract Research Organization (CRO) that supports their customers in the clinical development of pharmaceuticals, medical devices, and biologics. SCRO’s customers include pharmaceutical, biotech, and medical device companies, as well as academia. As a leading CRO in the Nordic countries, SCRO is headquartered in Uppsala, Sweden and operates in Norway, Sweden, Denmark, and Finland. SCRO’s clinical project portfolio also includes other parts of Europe and the rest of the world, thanks to its strong partnerships with other CROs and life science organizations.
Cardialysis is a full-service CRO with an exclusive focus on cardiology, providing the full range of clinical research services. Among its services, it is world-renowned for trial design, endpoint adjudication, biostatistics, and cardiovascular core laboratory capabilities. Cardialysis is headquartered in Rotterdam, The Netherlands, and is proud of its monitoring network in Western and Eastern European countries, as well as outside Europe via a network of preferred CRO partners. Cardialysis executes commercial and non-commercial studies, with device, pharma, and academic partners.
A commitment to advancing clinical research – together
SCRO and Cardialysis have decades of expertise in the field of clinical research, with a common goal of improving patient care and developing new treatments. With their broad experience and successful track records, the two companies have a unique opportunity to use their knowledge and expertise to advance clinical research in both countries.
“We are honored to represent Sweden in this strategic collaboration with Cardialysis. Our shared goal is to help as many patients as possible benefit from new and improved therapies,” said Ulrika Hammarström Lüllmaa, CEO at SCRO.
Learn more about SCRO and Cardialysis.
Related news:
Samlade satsningar på forskning och entreprenörskap i Uppsala ger resultat
